Radiant Biotherapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $35M

  • Investors
  • 10

Radiant Biotherapeutics General Information

Description

Developer of a modular, multi-valent, and multi-specific platform intended to create antibodies for the treatment of cancer, inflammation, and infections. The company's platform offers multi-functional biologics to tackle difficult-to-treat diseases such as cancer, autoimmune diseases, and infectious diseases, enabling healthcare professionals to exploit avidity and binding power coupled with multi-specificity to deliver potent multi-functional biologics with the potential to unlock cures for patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 686 Bay Street, PGCRL 21.9430.X
  • Admin Room 21.9800 U1 E
  • Toronto, Ontario M5G 0A4
  • Canada
+1 (437)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 686 Bay Street, PGCRL 21.9430.X
  • Admin Room 21.9800 U1 E
  • Toronto, Ontario M5G 0A4
  • Canada
+1 (437)

Radiant Biotherapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Radiant Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 27-Aug-2024 $35M Completed Pre-Clinical Trials
4. Seed Round 25-Apr-2023 Completed Pre-Clinical Trials
3. Accelerator/Incubator 22-Dec-2020 Completed Startup
2. Accelerator/Incubator 01-Sep-2020 Completed Startup
1. University Spin-Out 07-Aug-2020 Completed Startup
To view Radiant Biotherapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Radiant Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a modular, multi-valent, and multi-specific platform intended to create antibodies for the treatment of can
Drug Discovery
Toronto, Canada
14 As of 2024

Horgen, Switzerland
 

La Jolla, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Radiant Biotherapeutics Competitors (3)

One of Radiant Biotherapeutics’s 3 competitors is Numab Therapeutics, a Venture Capital-Backed company based in Horgen, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Numab Therapeutics Venture Capital-Backed Horgen, Switzerland
Inhibrx Formerly VC-backed La Jolla, CA
IGM Biosciences Formerly VC-backed Mountain View, CA
You’re viewing 3 of 3 competitors. Get the full list »

Radiant Biotherapeutics Patents

Radiant Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023407259-A1 Multivalent and multispecific cytokine antagonists Pending 18-Dec-2022
EP-4634237-A1 Multivalent and multispecific cytokine antagonists Pending 18-Dec-2022
US-20260209339-A1 Multivalent and multispecific cytokine antagonists Pending 18-Dec-2022
WO-2024130394-A1 Multivalent and multispecific cytokine antagonists Inactive 18-Dec-2022
AU-2023407260-A1 Multivalent hematopoietic cell engagers or activators Pending 18-Dec-2022 A61K47/62
To view Radiant Biotherapeutics’s complete patent history, request access »

Radiant Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Radiant Biotherapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aberdeen Investments (Scotland) Asset Manager Minority
BDC Capital Growth/Expansion Minority
Gates Foundation Not-For-Profit Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
SickKids Corporation Minority
You’re viewing 5 of 10 investors. Get the full list »

Radiant Biotherapeutics FAQs

  • When was Radiant Biotherapeutics founded?

    Radiant Biotherapeutics was founded in 2020.

  • Where is Radiant Biotherapeutics headquartered?

    Radiant Biotherapeutics is headquartered in Toronto, Canada.

  • What is the size of Radiant Biotherapeutics?

    Radiant Biotherapeutics has 14 total employees.

  • What industry is Radiant Biotherapeutics in?

    Radiant Biotherapeutics’s primary industry is Drug Discovery.

  • Is Radiant Biotherapeutics a private or public company?

    Radiant Biotherapeutics is a Private company.

  • What is Radiant Biotherapeutics’s current revenue?

    The current revenue for Radiant Biotherapeutics is .

  • How much funding has Radiant Biotherapeutics raised over time?

    Radiant Biotherapeutics has raised $43.1M.

  • Who are Radiant Biotherapeutics’s investors?

    Aberdeen Investments (Scotland), BDC Capital, Gates Foundation, Alexandria Venture Investments, and SickKids are 5 of 10 investors who have invested in Radiant Biotherapeutics.

  • Who are Radiant Biotherapeutics’s competitors?

    Numab Therapeutics, Inhibrx, and IGM Biosciences are competitors of Radiant Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process